Literature DB >> 5107415

Utilization of iron dextran.

A G Davies, M R Beamish, A Jacobs.   

Abstract

The utilization of iron dextran was investigated in normal subjects, in patients with iron-deficiency anaemia, and in anaemias associated with rheumatoid arthritis, reticulosis, and uraemia. Utilization of iron for haemoglobin formation at 14 days was found to be depressed in patients with rheumatoid arthritis, reticulosis, and uraemia, but when a concomitant iron-deficiency anaemia was present utilization was significantly increased. When iron dextran is used to treat anaemias in such conditions an optimum therapeutic response will be obtained only when bone marrow iron stores are absent.

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 5107415      PMCID: PMC1795105          DOI: 10.1136/bmj.1.5741.146

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  6 in total

1.  DEFECTIVE REUTILIZATION OF IRON IN THE ANEMIA OF INFLAMMATION.

Authors:  F I HAURANI; W BURKE; E J MARTINEZ
Journal:  J Lab Clin Med       Date:  1965-04

2.  Reutilization of iron in anemia complicating malignant neoplasma.

Authors:  F I HAURANI; K YOUNG; L M TOCANTINS
Journal:  Blood       Date:  1963-07       Impact factor: 22.113

3.  Characteristics of iron dextran utilization in man.

Authors:  P A Henderson; R S Hillman
Journal:  Blood       Date:  1969-09       Impact factor: 22.113

4.  Iron metabolism in the anaemia of chronic renal failure. Effects of dialysis and of parenteral iron.

Authors:  R A Carter; J B Hawkins; B H Robinson
Journal:  Br Med J       Date:  1969-07-26

5.  Measurement of plasma volume by means of 59Fe-labelled dextran and Evans blue compared.

Authors:  R J Wilson; I H Mills
Journal:  J Clin Pathol       Date:  1970-05       Impact factor: 3.411

6.  METHOD FOR THE AUTOMATIC DETERMINATION OF SERUM IRON.

Authors:  D S YOUNG; J M HICKS
Journal:  J Clin Pathol       Date:  1965-01       Impact factor: 3.411

  6 in total
  2 in total

Review 1.  The anaemia of chronic disorders.

Authors:  D Samson
Journal:  Postgrad Med J       Date:  1983-09       Impact factor: 2.401

Review 2.  Safety aspects of parenteral iron in patients with end-stage renal disease.

Authors:  G Sunder-Plassmann; W H Hörl
Journal:  Drug Saf       Date:  1997-10       Impact factor: 5.606

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.